31results about "Micromachined delivery" patented technology

An embodiment relates to a system comprising a fluid chamber containing a fluid; an Active Wearable Medical Device (AWMD) comprising a permeability module configured to allow ingress of fluid from the fluid chamber to an osmotic agent chamber via a semi-permeable membrane to generate osmotic pressure; a piston that moves longitudinally in response to the osmotic pressure; a drug chamber comprising a drug and a valve module configured to enable one-way drug flow from the chamber to outside the AWMD; a sensor module to measure piston displacement and provide real-time data; and an electronic module configured to regulate drug ejection based on the displacement data, ensuring dose-to-dose volume variation remains within ±25%. A machine learning model triggers alerts if dosing deviates from threshold limits. A channel is fluidically coupled to the AWMD and delivers the drug to the subject. The AWMD is externally worn and not implanted.

Drug delivery devices and methods of controlled drug delivery to a patient are provided. The drug delivery device may include one or two microchip elements, each of which has a body portion with one or more drug release apertures in fluid communication with at least one containment reservoir. The drug release apertures are closed off by one or more reservoir caps which can be electrically activated to open the drug release apertures. The drug delivery device also includes (i) a drug formulation disposed in the at least one containment reservoir, and (ii) at least one drug-permeable membrane. In some cases, an outer housing is spaced a distance from an exterior wall of the body portion of the microchip element, the outer housing includes the at least one drug-permeable membrane, and a depot space is defined between the drug-permeable membrane and the exterior wall of the body portion of the microchip element.

The present invention provides drug delivery devices and methods for controlled drug delivery to a patient. The drug delivery devices can include one or two microchip elements, each having a body portion with one or more drug release apertures in fluid communication with at least one contained reservoir. The drug release apertures are closed by one or more reservoir covers that can be electrically activated to open the drug release apertures. The drug delivery devices further include (i) a drug formulation disposed in the at least one contained reservoir, and (ii) at least one drug permeable membrane. In some cases, an outer housing is spaced apart from an outer wall of the body portion of the microchip element, the outer housing includes the at least one drug permeable membrane, and defines a reservoir space between the drug permeable membrane and the outer wall of the body portion of the microchip element.

The object of the invention is a method for obtaining an injectable biocompatible drug delivery vehicle, cell carrier or combinations thereof, in the form of microscaffolds, characterised in that it comprises the following steps: a) preparation of a solution containing a polymer and at least one solvent; b) formation of fibres with a diameter of 50 nm to 10 pm on a flat collector by electrospinning; c) laser cutting of the nonwoven fabric formed on the collector into individual separate scaffold microscaffolds with a thickness of 0.01 to 0.2 mm and either a cylinder-form with a base diameter of 0.1 to 0.4 mm or a prism-form with a base edge length of 0.04 to 0.4 mm; d) separation of the microscaffolds from the collector; e) chemical modification of the microscaffolds by suspending them in an aqueous NaOH solution of 0.001-1 M concentration for 1-120 min or physical modification by suspending them in an aqueous protein solution of 0.001-0.5 M concentration for 2-120 min; f) removing excess NaOH or protein from the surface of the microscaffolds. A further object of the invention is an injectable delivery composition comprising a buffer and biocompatible in vitro mutually non-aggregating drug vehicles, cell carriers, or combinations thereof, characterised in that the vehicles / carriers are electrospun fibre microscaffolds fabricated with the method according to the invention, wherein each microscaffold is a single vehicle / carrier with a thickness of 0.005 to 0.2 mm and the shape of a cylinder with a base diameter of 0.05 to 0.5 mm or a prism with a base edge length of 0.05 to 0.5 mm, the surface of which is modified chemically with NaOH solution or physically with a protein solution, whereby the microscaffolds suspended in the buffer form a suspension of non-aggregating microparticles. Another object of the invention is the use of the composition according to the invention in the treatment of bone, cartilage, and intervertebral disc injuries.

To provide drug delivery devices and methods of controlled drug delivery to a patient.SOLUTION: A drug delivery device may include one or two microchip elements, each of which has a body portion with one or more drug release apertures in fluid communication with at least one containment reservoir. The drug release apertures are closed off by one or more reservoir caps which can be electrically activated to open the drug release apertures. The drug delivery device also includes (i) a drug formulation disposed in the at least one containment reservoir, and (ii) at least one drug-permeable membrane. In some cases, an outer housing is spaced a distance from an exterior wall of the body portion of the microchip element, the outer housing includes the at least one drug-permeable membrane, and a depot space is defined between the drug-permeable membrane and the exterior wall of the body portion of the microchip element.SELECTED DRAWING: Figure 2

The present disclosure provides a drug delivery device. The drug delivery device is taken orally by a patient, and then activates within the gastrointestinal (GI) tract of the patient. Upon activation, arms of the drug delivery device expand, and penetrating tips penetrate the GI tract walls. A driver then drives a plunger within the drug delivery device, pushing a drug through the penetrating tips and through the GI tract walls of the patient. After a period of time, part of the drug delivery device dissolves and the drug delivery device passes through the GI tract.

Embodiments provide devices, preparations and methods for delivering therapeutic agents (TAs) such as clotting factors (CFs, e.g., Factor 8) within the GI tract. Many embodiments provide a swallowable device e.g., a capsule for delivering TAs into the intestinal wall (IW). Embodiments also provide TA preparations configured to be contained within the capsule, advanced from the capsule into the IW and / or surrounding tissue (ST) and degrade to release the TA into the bloodstream to produce a therapeutic effect (e.g., improved clotting). The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the IW or ST (e.g., the peritoneal cavity). Embodiments are particularly useful for delivery of CFs for treatment of clotting disorders (e.g., hemophilia) where such CFs are poorly absorbed and / or degraded within the GI tract.

Embodiments of the present invention are directed to a liquid delivery apparatus. A non-limiting example of the apparatus includes a substrate including a cavity formed in a surface of the substrate. The apparatus can also include a membrane disposed on the surface of the substrate covering an opening of the cavity. The apparatus can also include a hydrophobic layer disposed on the membrane. The apparatus can also include a seal disposed between the membrane and the substrate, wherein the seal surrounds the opening of the cavity. The apparatus can also include an electrode layer coupled to the membrane.

The present disclosure provides a drug delivery device. The drug delivery device is orally ingested by a patient and then activated within the patient's gastrointestinal (GI) tract. Upon activation, a resilient arm within the drug delivery device expands and engages the GI tract wall. A driver then drives a plunger within the drug delivery device, pushing a drug through a channel in the resilient arm and through the patient's GI tract wall. After a period of time, at least a portion of the drug delivery device dissolves, and the drug delivery device passes through the GI tract.

A method for identifying the presence or progression of hypoxic ischemic brain injury includes, for each subset of one or more subsets of a three-dimensional medical image of a head of a patient: (i) inputting said each subset into a machine-learning model, (ii) extracting one or more features or feature maps from the machine-learning model, and (iii) constructing, based on the one or more features or feature maps, one of a sequence of vectors. The sequence of vectors is then pooled to obtain a scan-level vector that is used to obtain a score indicating HIBI presence or progression in the patient. For example, the scan-level vector can be inputted into a pre-trained classifier that generates the score based on the scan-level vector. The machine-learning model may be a pre-trained conventional neural network or support vector machine.

The present disclosure provides a drug delivery device. The drug delivery device is orally ingested by a patient and then activated within the patient's gastrointestinal (GI) tract. Upon activation, a resilient arm within the drug delivery device expands and engages the GI tract wall. A driver then drives a plunger within the drug delivery device, pushing a drug through a channel in the resilient arm and through the patient's GI tract wall. After a period of time, at least a portion of the drug delivery device dissolves, and the drug delivery device passes through the GI tract.

A scalable method of continuous microfluidic synthesis of tannic acid-iron III (TA-FeIII) network (TFN) nanocapsules of a hydrophobic drug; a scalable method of continuous microfluidic synthesis of epigallocatechin-3-gallate iron III (EGCG-FeIII) network, (EFN) nanocapsules; hydrophobic drug nanocapsules synthesized in accordance with the method; and a method of administering a hydrophobic drug to a patient in need thereof by administering to the patient the hydrophobic drug nanocapsules.

An active drug dispensing ophthalmic device can include a plurality of drug reservoirs, each covered by an electrode, and a controller-responder architecture. Electrodissolution of each electrode and the associated drug release can be governed by a controller via a responder. Employing a controller-responder architecture can reduce the number of connections and separate electrical signals required to actively dispense drugs from each of the plurality of drug reservoirs. The controller can be connected to a plurality of responders via a control line bundle and each of the plurality of responders can deliver signals to the electrode(s) covering a portion of a plurality of drug reservoirs. The controller-responder architecture can also employ a composite electrical communication signal to even further decrease the number of electrical connections required from a controller to each of the responders.

A hollow body has a bottom, an upper end wall, and side walls extending between the bottom and the upper end wall. The upper end wall and side walls are made of metal. The cavity within the hollow body has a volume in the range between 1 picoliter to 1,000 picoliter. The upper end wall comprises at least one opening. The hollow body is suitable for encapsulating small amounts of liquid, or a small micro-electromechanical system, and may be used for the controlled release of pharmaceutical components.

The present disclosure relates to a method of treating a gastrointestinal (GI) inflammatory disease or condition in a subject in need thereof, comprising topically administering to the subject a pharmaceutical formulation comprising a therapeutically effective amount of a JAK inhibitor, said topical administration comprising orally administering an ingestible device to the subject, said device containing the pharmaceutical formulation, and releasing the pharmaceutical formulation from the device (a) to a section or subsection of the subject's GI tract containing one or more inflammatory disease sites; or (b) proximal to a section or subsection of the subject's GI tract containing one or more inflammatory disease sites, wherein the onset of the pharmaceutical formulation release occurs before the ingestible device reaches the disease site.

Described herein are unit cells including a base plate; a top plate; and a lumen extending longitudinally from the base plate to the top plate, the lumen defined by a side wall formed from a plurality of cojoined panels extending between a bottom surface of the top plate and a top surface of the base plate. The unit cell can be magnetically actuatable, such that the unit cell can be reversibly transitioned between a contracted configuration, an extended configuration, or a combination thereof using an applied magnetic field.

The invention belongs to the technical field of biological medicine, and particularly relates to a noninvasive controllable flexible biological electronic patch for treating diabetic erectile dysfunction. The erectile dysfunction related to diabetes is difficult to recover due to long-term damage of a cavernous body microenvironment, traditional oral administration or cavernous body injection treatment has poor targeting, non-uniform distribution and complication risk, and long-term curative effect is difficult to realize. The invention provides a flexible and attachable bioelectronic patch which is used for noninvasively, painlessly and controllably adjusting an erectile tissue microenvironment. The device synergistically promotes local vascular active factor expression and endothelial repair through mild electrical stimulation, realizes uniform transdermal delivery of drug molecules, shows high delivery efficiency and cell activity, and significantly improves cavernous body blood flow and cell functions. In an in-vitro cell model and a diabetic animal model, the device shows better vascular regeneration and function recovery effects than traditional medicine or injection therapy.

This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a PDE4 inhibitor.

Device (1) for the passive release of a substance into a solution, said device allowing the tracking of the release by means of intra body communication, and comprising a transmitter (2) configured to generate an alternating electrical signal, powered by a battery and provided with a first electrode (3) and with a second electrode (4); a passive release component (5) made of electrically insulating material and comprising said substance, the passive release component (5) degradable in the environment of interest allows the release of said substance, said material (5) incorporates the electrode (3); a stable, electrically conductive, component (6), not degradable in the solution for the release into which the second electrode (4) is incorporated.

Gastric residence systems for administration of risperidone are disclosed. Features which enhance gastric retention during the desired residence time and which allow for more precise control over residence time are disclosed, including circumferential filaments connecting the arms of a stellate gastric residence system; improved time-dependent and enteric disintegrating matrices (linkers); and release rate-modulating polymer coatings which are resistant to change in release rate properties during heat-assisted assembly or thermal cycling. Combinations of these features are also disclosed.

A drug delivery device and a method for controlled drug delivery to a patient are provided. The drug delivery device may include one or two microchip elements, each having a body portion with one or more drug release openings in fluid communication with at least one storage reservoir. The drug release openings are closed by one or more reservoir caps that can be electrically activated to open the drug release openings. The drug delivery device also includes (i) a drug formulation disposed in the at least one storage reservoir, and (ii) at least one drug-permeable membrane. In some cases, an outer housing is spaced apart from an outer wall of the body portion of the microchip element, the outer housing including the at least one drug-permeable membrane, and a depot space is defined between the drug-permeable membrane and the outer wall of the body portion of the microchip element.

Drug delivery devices and methods of controlled drug delivery to a patient are provided. The drug delivery device may include one or two microchip elements, each of which has a body portion with one or more drug release apertures in fluid communication with at least one containment reservoir. The drug release apertures are closed off by one or more reservoir caps which can be electrically activated to open the drug release apertures. The drug delivery device also includes (i) a drug formulation disposed in the at least one containment reservoir, and (ii) at least one drug-permeable membrane. In some cases, an outer housing is spaced a distance from an exterior wall of the body portion of the microchip element, the outer housing includes the at least one drug-permeable membrane, and a depot space is defined between the drug-permeable membrane and the exterior wall of the body portion of the microchip element.

An active molecule delivery system whereby active molecules can be released on demand and / or a variety of different active molecules can be delivered from the same system and / or different concentrations of active molecules can be delivered from the same system. The invention is well-suited for delivering pharmaceuticals to patients transdermally. In some embodiments, the system includes two separate reservoirs and a mixing area thereby allowing precursors to be mixed immediately before transdermal delivery.

Gastric residence systems for administration of risperidone are disclosed. Features which enhance gastric retention during the desired residence time and which allow for more precise control over residence time are disclosed, including circumferential filaments connecting the arms of a stellate gastric residence system; improved time-dependent and enteric disintegrating matrices (linkers); and release rate-modulating polymer coatings which are resistant to change in release rate properties during heat-assisted assembly or thermal cycling. Combinations of these features are also disclosed.

This invention discloses a customizable MOF-based magnetically controlled microrobot, its fabrication method, and its applications, belonging to the field of microrobot technology. The fabrication method includes the following steps: coupling a micro / nano fabrication template method with a two-phase interface self-assembly method to prepare a magnetic MOF microrobot; modifying the magnetic MOF microrobot with amino groups using a ligand exchange method; and then loading lipase using an ion adsorption method to finally obtain the customizable MOF-based magnetically controlled microrobot. The microrobot prepared by this invention can achieve efficient actuation under a magnetic field and can achieve precise control and perform complex tasks; at the same time, the fabrication method disclosed in this invention is simple and easy to implement, and is a process for mass-producing customizable magnetically controlled MOF microrobots.

Described herein are drug and other active agent transdermal delivery systems and devices to deliver active agents to skin or mucosa of a subject, and methods of delivering such active agents. In particular, systems, methods, and devices are described that control the concentration and timing of active agent delivery. Such systems or devices may include a transdermal membrane and a temperature control element for heating and / or cooling a portion of the transdermal delivery system to provide pulsatile active agent delivery through the transdermal membrane.

The invention relates to a two-stage microchip drug delivery device and method. Drug delivery devices and methods for controlled drug delivery to a patient are provided. The drug delivery device may include one or two microchip elements, each microchip element having a body portion with one or more drug release apertures in fluid communication with at least one containment reservoir. The drug release aperture is closed by one or more reservoir caps, which can be electrically activated to open the drug release aperture. The drug delivery device further includes (i) a drug formulation disposed in the at least one containment reservoir, and (ii) at least one drug permeable membrane. In some cases, a housing is spaced a distance from an outer wall of the body portion of the microchip element, the housing including the at least one drug permeable membrane, and a reservoir space is defined between the drug permeable membrane and the outer wall of the body portion of the microchip element.

The present disclosure relates to devices and systems for targeted and controlled delivery of a therapeutic agent to a treatment site of an eye. Particularly, aspects are directed to a therapeutic agent delivery device (200) that includes a polymeric substrate (205) having a release region (210), a delivery region, and a receiving region; one or more reservoirs (215) formed within the release region (210); a therapeutic agent disposed within the one or more reservoirs (215); an active, passive, or combination thereof controlled release mechanism for release of the therapeutic agent from the one or more reservoirs (215) into the delivery region; and a circuit (275) formed on the polymeric substrate (205), the circuit (275) having a current source, a first iontophoresis electrode located within the delivery region for transport of the therapeutic agent from the delivery region into a target tissue via electromigration, and a second iontophoresis electrode located within the receiving region for maintaining electroneutrality within the tissue.

Described herein are unit cells including a base plate; a top plate; and a lumen extending longitudinally from the base plate to the top plate, the lumen defined by a side wall formed from a plurality of cojoined panels extending between a bottom surface of the top plate and a top surface of the base plate. The unit cell can be magnetically actuatable, such that the unit cell can be reversibly transitioned between a contracted configuration, an extended configuration, or a combination thereof using an applied magnetic field.

To provide an oral drug delivery device having expanding arms to be activated in the small intestine to deliver a drug through a gastrointestinal wall.SOLUTION: A drug delivery device 100 is taken orally by a patient, and then activates within the gastrointestinal (GI) tract of the patient. Upon activation, resilient arms 215 within the drug delivery device 100 expand and engage the GI tract walls. A driver then drives a plunger 340 within the drug delivery device 100, pushing a drug through a channel 213 in the resilient arms 215 and through the GI tract walls of the patient. After a period of time, at least a portion of the drug delivery device 100 dissolves and the drug delivery device 100 passes through the GI tract.SELECTED DRAWING: Figure 1